UY29454A1 - Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos - Google Patents

Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos

Info

Publication number
UY29454A1
UY29454A1 UY29454A UY29454A UY29454A1 UY 29454 A1 UY29454 A1 UY 29454A1 UY 29454 A UY29454 A UY 29454A UY 29454 A UY29454 A UY 29454A UY 29454 A1 UY29454 A1 UY 29454A1
Authority
UY
Uruguay
Prior art keywords
amino
pyrimidine
disease
derivatives
tiazol
Prior art date
Application number
UY29454A
Other languages
English (en)
Inventor
Nordvall Gunnar
Ray Colin
Rein Tobias
Sohn Daniel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29454A1 publication Critical patent/UY29454A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Nuevos derivados 5-sustituidos de 7-amino-(1,3) tiazol (4,5-d) pirimidina de fórmula (I)en los que R1, R2, R3, R4 u R5 son como se define en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, procesos para su preparación, composiciones farmacéuticas que los comprenden y aplicaciones. Los compuestos de fórmula (I) son antagonistas de receptor CX3CR1 y son así particularmente útiles para tratamiento o profilaxis de trastornos neurodegenerativos, enfermedad desmielizante, trastornos ateroscleróticos cardio y cerebrovasculares, enfermedad arterial periferal, arthritis reumatoide, enfermedades pulmonares como COPD/enfermedad pulmonaria obstructiva crónica/, asma o dolor.
UY29454A 2005-04-06 2006-04-04 Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos UY29454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06

Publications (1)

Publication Number Publication Date
UY29454A1 true UY29454A1 (es) 2006-11-30

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29454A UY29454A1 (es) 2005-04-06 2006-04-04 Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos

Country Status (31)

Country Link
US (2) US7947693B2 (es)
EP (1) EP1869056B1 (es)
JP (1) JP5165553B2 (es)
KR (1) KR101335055B1 (es)
CN (1) CN101193897B (es)
AR (1) AR055890A1 (es)
AT (1) ATE487727T1 (es)
AU (1) AU2006231836B2 (es)
BR (1) BRPI0609738A2 (es)
CA (1) CA2604017C (es)
CY (1) CY1111316T1 (es)
DE (1) DE602006018124D1 (es)
DK (1) DK1869056T3 (es)
ES (1) ES2354450T3 (es)
HK (1) HK1118556A1 (es)
HR (1) HRP20110047T1 (es)
IL (1) IL185912A0 (es)
MX (1) MX2007012060A (es)
NO (1) NO20075603L (es)
NZ (1) NZ561460A (es)
PL (1) PL1869056T3 (es)
PT (1) PT1869056E (es)
RS (1) RS51581B (es)
RU (1) RU2419623C2 (es)
SA (1) SA06270072B1 (es)
SI (1) SI1869056T1 (es)
TW (1) TW200714605A (es)
UA (1) UA90707C2 (es)
UY (1) UY29454A1 (es)
WO (1) WO2006107258A1 (es)
ZA (1) ZA200708187B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
WO2008039139A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
SI2254870T1 (sl) 2008-03-07 2016-05-31 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1
PL2262777T3 (pl) 2008-03-07 2016-08-31 Acraf Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
CA2714436C (en) 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2010132999A1 (en) 2009-05-21 2010-11-25 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHODS OF INHIBITING THE METASTASIS OF CANCER
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
US9550732B2 (en) 2013-03-12 2017-01-24 Eisai R&D Management Co., Ltd. Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
BR112016006319A2 (pt) * 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
US20180222922A1 (en) * 2015-06-08 2018-08-09 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
WO2018204370A1 (en) 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
WO2024083933A1 (en) 2022-10-19 2024-04-25 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (es) * 1955-01-03
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
ZA909847B (en) 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
CA2326884A1 (en) * 1998-04-03 1999-10-14 Dupont Pharmaceuticals Company Thiazolo¬4,5-d|pyrimidines and pyridines as corticotropin releasing factor (crf) antagonists
ES2283107T3 (es) 1998-05-01 2007-10-16 Eli Lilly And Company Glicopeptidos modificados en n1.
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
AU2001232556A1 (en) * 2000-02-11 2001-08-20 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
EP3597262B1 (en) * 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulation for intracutaneous injection
US20070142386A1 (en) * 2003-10-07 2007-06-21 Astrazeneca New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
RU2419623C2 (ru) 2011-05-27
EP1869056A1 (en) 2007-12-26
TW200714605A (en) 2007-04-16
CA2604017C (en) 2012-03-06
KR101335055B1 (ko) 2013-12-02
US9440992B2 (en) 2016-09-13
RU2007140551A (ru) 2009-05-20
WO2006107258A1 (en) 2006-10-12
KR20080004483A (ko) 2008-01-09
NZ561460A (en) 2010-12-24
SI1869056T1 (sl) 2011-02-28
AU2006231836A1 (en) 2006-10-12
AR055890A1 (es) 2007-09-12
CY1111316T1 (el) 2015-08-05
EP1869056B1 (en) 2010-11-10
NO20075603L (no) 2008-01-04
PL1869056T3 (pl) 2011-04-29
CN101193897B (zh) 2010-12-01
HRP20110047T1 (hr) 2011-03-31
PT1869056E (pt) 2011-01-13
SA06270072B1 (ar) 2009-02-07
BRPI0609738A2 (pt) 2011-10-18
ZA200708187B (en) 2008-11-26
MX2007012060A (es) 2007-12-13
UA90707C2 (en) 2010-05-25
CN101193897A (zh) 2008-06-04
HK1118556A1 (en) 2009-02-13
JP2008535835A (ja) 2008-09-04
AU2006231836B2 (en) 2010-07-15
CA2604017A1 (en) 2006-10-12
IL185912A0 (en) 2008-01-06
ES2354450T3 (es) 2011-03-15
RS51581B (en) 2011-08-31
US20080214578A1 (en) 2008-09-04
JP5165553B2 (ja) 2013-03-21
ATE487727T1 (de) 2010-11-15
US7947693B2 (en) 2011-05-24
DK1869056T3 (da) 2011-02-07
EP1869056A4 (en) 2010-02-17
DE602006018124D1 (de) 2010-12-23
US20110092519A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
UY29454A1 (es) Derivados novedosos de 7-amino-(1,3) tiazol(4,5-d) pirimidina 5-sustituidos
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
UY29451A1 (es) Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
CL2009000029A1 (es) Compuestos heterocíclicos derivados de piridina sustituida; procedimiento de preparación de los compuestos; composición farmacéutica; su uso en el tratamiento de trastornos mediados por el receptor alk-5 o alk-4, útiles en el tratamiento de la hipertensión pulmonar, enfemedades renales, artritis, osteoporosis, entre otras.
GT200600013A (es) Compuestos organicos
CL2012000981A1 (es) Compuestos derivados de 5-etinil-2-[(3-fenil-1h-pirazolo[3.4-d]pirimidin-1-il)metil]quinazolin-4(3h)-ona, inhibidores de fosfoinositida 3-quinasa compuestos intermediarios; sin accion farmacologica; composicion farmaceutica; utiles en el tratamiento de epoc, asma fibrosis quistica y pulmonar, sarcoidosis, entre otras.
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
CL2007002043A1 (es) Compuestos derivados de pirimidinas sustituidos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, hipertension pulmonar, fibrosis pulmonar, fibro
CY1112370T1 (el) Παραγωγα σουλφοναμιδης και χρηση αυτων στη ρυθμιση των μεταλλοπρωτεϊνασων
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
UY28720A1 (es) Uso de pteridinas sustituidas para el tratamiento de enfermedades de la vías respiratorias
GT200500281A (es) Compuestos organicos.
WO2008039139A8 (en) Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
UY31734A (es) Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona
CY1111105T1 (el) Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6
EA200701758A1 (ru) Замещённые арильные производные 1,4-пиразина
UY30612A1 (es) Derivados 5,7 disustituidos de la [1,3]tiazolo[4,5,d]pirimidin-2(3h)-ona, proceso de preparacion y aplicaciones
CL2008002696A1 (es) Compuestos derivados de hidroxi-benzamidas, antagonistas de receptores muscarinicos; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; y uso del compuesto para el tratamiento de enfermedades de las vias respiratorias obstructivas o inflamatorias, broncoconstriccion, asma, bronquitis.
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160810